With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Year 2015-16 and 2016-17 with the issues involved relating to levy of penalty under section 272A(2)(g) and section 271C of the Income Tax Act, 1961 (“the Act” for short). All the appeals arise from ...
14h
UAE Moments on MSN10 Valuable Inventions Made in the PhilippinesThe Philippines is not only known for its stunning landscapes and warm-hearted people but also for its brilliant minds that ...
19h
Zacks Investment Research on MSNNektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results